Dechra acquires the rights to Malaseb®

Dechra acquires the rights to Malaseb®

Friday, March 4, 2022

Dechra is pleased to announce the licensing rights of the Malaseb® brand of dermatology products in the United States with Dermcare of Australia.

This partnership complements the existing Dechra dermatology by offering a well-known and trusted brand.

Mike Eldred, President of Dechra North America, stated, “The Malaseb line of dermatology products strengthens the popular Dechra dermatology product line by offering a brand that many veterinarians use and trust.”

About Dechra:

Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole), the Vetivex® line of parenteral fluids, and Phycox® joint health supplements. Osurnia® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto®, MiconaHex+Triz®, MalAcetic®, and oral anti-infective product lines, including Marboquin® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz® (mirtazapine transdermal ointment), Porus® One, and Redonyl® Ultra Feline to the portfolio supports the underserved feline market.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike EldredPresident, North American Operations, Dechra Veterinary Products,

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products,